argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-05-19 14:50 |
argenx announces full exercise of underwriters’ option to purchase additional A…
|
English | 59.5 KB | ||
| 2017-05-18 07:17 |
argenx raises approximately $100 million gross proceeds with NASDAQ IPO
|
English | 91.5 KB | ||
| 2017-05-16 07:26 |
argenx announces size of initial public offering in the United States increased…
|
English | 92.3 KB | ||
| 2017-05-08 14:28 |
argenx announces launch of proposed initial public offering in the United States
|
English | 139.7 KB | ||
| 2017-05-04 07:18 |
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthen…
|
English | 23.6 KB | ||
| 2017-05-03 07:19 |
argenx reports first quarter 2017 financial results and provides business update
|
English | 114.8 KB | ||
| 2017-04-26 16:23 |
argenx announces results of Annual General Meeting 2017
|
English | 27.6 KB | ||
| 2017-04-24 08:39 |
argenx files registration statement for a proposed public offering in the Unite…
|
English | 89.4 KB | ||
| 2017-04-14 07:21 |
argenx receives first preclinical milestone payment in AbbVie collaboration
|
English | 19.7 KB | ||
| 2017-04-12 07:20 |
argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refract…
|
English | 107.9 KB | ||
| 2017-03-31 07:31 |
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX…
|
English | 47.1 KB | ||
| 2017-03-21 08:28 |
argenx announces collaboration with Broteio Pharma to develop therapeutic antib…
|
English | 39.2 KB | ||
| 2017-03-15 11:08 | English | 4.0 MB | |||
| 2017-03-15 07:44 |
argenx reports fourth quarter business update and full year 2016 financial resu…
|
English | 431.3 KB | ||
| 2017-03-15 07:39 |
argenx announces Annual General Meeting of Shareholders 26 April 2017
|
English | 103.5 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
